Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

PhaseBio Pharmaceuticals Inc.

PHASQ
Current price
0.0001 USD 0 USD (0.00%)
Last closed 0.0001 USD
Company
ISIN US7172241090
Sector Healthcare
Industry Biotechnology
Exchange PINK
Capitalization 4 986 USD
Yield for 12 month -75.00 %
1Y
3Y
5Y
10Y
15Y
PHASQ
21.11.2021 - 28.11.2021

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on June 26, 2024. Address: 1 Great Valley Parkway, Malvern, PA, United States, 19355

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

1 USD

P/E ratio

Dividend Yield

Current Year

+10 831 USD

Last Year

+320 000 USD

Current Quarter

+208 000 USD

Last Quarter

+117 000 USD

Current Year

+10 831 USD

Last Year

+320 USD

Current Quarter

+208 000 USD

Last Quarter

+117 000 USD

Key Figures PHASQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -102 262 000 USD
Operating Margin TTM -12169.23 %
PE Ratio
Return On Assets TTM -106.07 %
PEG Ratio
Return On Equity TTM
Wall Street Target Price 1 USD
Revenue TTM 818 000 USD
Book Value -2.36 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -98 %
Dividend Yield
Gross Profit TTM -91 276 000 USD
Earnings per share -2.14 USD
Diluted Eps TTM -2.14 USD
Most Recent Quarter II 2022
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics PHASQ

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History PHASQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation PHASQ

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 0.044
Price Sales TTM 0.0061
Enterprise Value EBITDA 0.0239
Price Book MRQ 26.18

Financials PHASQ

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators PHASQ

For 52 weeks

0.0001 USD 0.001 USD
50 Day MA 0.0001 USD
Shares Short Prior Month 1 468 478
200 Day MA 0.0001 USD
Short Ratio 1.89
Shares Short 2 066 603
Short Percent 5.11 %